{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:24:22Z","timestamp":1787790262603,"version":"build-2784847793"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Cancer League of Eastern Switzerland"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Study goal<\/jats:title>\n                    <jats:p>We compared the survival rates of women with breast cancer (BC) detected within versus outside the mammography screening program (MSP) \u201cdonna\u201d.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We merged data from the MSP with the data from corresponding cancer registries to categorize BC cases as within MSP (screen-detected and interval carcinomas) and outside the MSP. We analyzed the tumor stage distribution, tumor characteristics and the survival of the women. We further estimated hazard ratios using Cox-regressions to account for different characteristics between groups and corrected the survival rates for lead-time bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified 1057 invasive (ICD-10: C50) and in-situ (D05) BC cases within the MSP and 1501 outside the MSP between 2010 and 2019 in the Swiss cantons of St. Gallen and Grisons. BC within the MSP had a higher share of stage I carcinoma (46.5% vs. 33.0%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), a smaller (mean) tumor size (19.1\u00a0mm vs. 24.9\u00a0mm,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), and fewer recurrences and metastases in the follow-up period (6.7% vs. 15.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). The 10-year survival rates were 91.4% for women within and 72.1% for women outside the MSP (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Survival difference persisted but decreased when women within the same tumor stage were compared. Lead-time corrected hazard ratios for the MSP accounted for age, tumor size and Ki-67 proliferation index were 0.550 (95% CI 0.389, 0.778;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) for overall survival and 0.469 (95% CI 0.294, 0.749;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) for BC related survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Women participating in the \u201cdonna\u201d MSP had a significantly higher overall and BC related survival rate than women outside the program. Detection of BC at an earlier tumor stage only partially explains the observed differences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-024-01841-6","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T09:01:51Z","timestamp":1716800511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Breast cancer patients enrolled in the Swiss mammography screening program \u201cdonna\u201d demonstrate prolonged survival"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7092-7480","authenticated-orcid":false,"given":"David","family":"Kuklinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Subelack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Eichenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Morant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"1841_CR1","unstructured":"Bulliard JL, Braendle K, Fracheboud J, Zwahlen M. Breast cancer screening programmes in Switzerland, 2010\u20132018; 2021."},{"key":"1841_CR2","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1038\/bjc.2013.177","volume":"108","author":"MG Marmot","year":"2013","unstructured":"Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108:2205\u201340.","journal-title":"Br J Cancer"},{"key":"1841_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0140-6736(99)06065-1","volume":"355","author":"PC G\u00f8tzsche","year":"2000","unstructured":"G\u00f8tzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet. 2000;355:129\u201334.","journal-title":"Lancet"},{"key":"1841_CR4","first-page":"A4246","volume":"58","author":"PC G\u00f8tzsche","year":"2011","unstructured":"G\u00f8tzsche PC. Relation between breast cancer mortality and screening effectiveness: systematic review of the mammography trials. Dan Med Bull. 2011;58:A4246.","journal-title":"Dan Med Bull"},{"key":"1841_CR5","unstructured":"Swiss Medical Board: Systematisches Mammographie-Screening; 2013."},{"key":"1841_CR6","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2217\/bmt.13.53","volume":"2","author":"SW Duffy","year":"2013","unstructured":"Duffy SW, Chen THH, Smith RA, Yen AMF, Tabar L. Real and artificial controversies in breast cancer screening. Breast Cancer Management. 2013;2:519\u201328.","journal-title":"Breast Cancer Management"},{"key":"1841_CR7","doi-asserted-by":"publisher","first-page":"e017806","DOI":"10.1136\/bmjopen-2017-017806","volume":"8","author":"C Herrmann","year":"2018","unstructured":"Herrmann C, Vounatsou P, Th\u00fcrlimann B, Probst-Hensch N, Rothermundt C, Ess S. Impact of mammography screening programmes on breast cancer mortality in Switzerland, a country with different regional screening policies. BMJ Open. 2018;8:e017806.","journal-title":"BMJ Open"},{"key":"1841_CR8","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3322\/caac.21754","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, Jemal A, Siegel RL. Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022;72:524\u201341.","journal-title":"CA Cancer J Clin"},{"key":"1841_CR9","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/cac2.12207","volume":"41","author":"S Lei","year":"2021","unstructured":"Lei S, Zheng R, Zhang S, Wang S, Chen R, Sun K, Zeng H, Zhou J, Wei W. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. Cancer Commun (London, England). 2021;41:1183\u201394.","journal-title":"Cancer Commun (London, England)"},{"key":"1841_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12916-022-02440-y","volume":"20","author":"ZL Lim","year":"2022","unstructured":"Lim ZL, Ho PJ, Khng AJ, Yeoh YS, Ong ATW, Tan BKT, Tan EY, Tan S-M, Lim GH, Lee JA, Tan VKM, Hu J, Li J, Hartman M. Mammography screening is associated with more favourable breast cancer tumour characteristics and better overall survival: case-only analysis of 3739 Asian breast cancer patients. BMC Med. 2022;20:239.","journal-title":"BMC Med"},{"issue":"Suppl 1","key":"1841_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1258\/jms.2012.012080","volume":"19","author":"S Njor","year":"2012","unstructured":"Njor S, Nystr\u00f6m L, Moss S, Paci E, Broeders M, Segnan N, Lynge E. Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. J Med Screen. 2012;19(Suppl 1):33\u201341.","journal-title":"J Med Screen"},{"key":"1841_CR12","doi-asserted-by":"publisher","first-page":"100111","DOI":"10.1016\/j.esmoop.2021.100111","volume":"6","author":"A Molassiotis","year":"2021","unstructured":"Molassiotis A, Tyrovolas S, Gin\u00e9-V\u00e1zquez I, Yeo W, Aapro M, Herrstedt J. Organized breast cancer screening not only reduces mortality from breast cancer but also significantly decreases disability-adjusted life years: analysis of the Global Burden of Disease Study and screening programme availability in 130 countries. ESMO open. 2021;6:100111.","journal-title":"ESMO open"},{"key":"1841_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/aje\/kwn120","volume":"168","author":"SW Duffy","year":"2008","unstructured":"Duffy SW, Nagtegaal ID, Wallis M, Cafferty FH, Houssami N, Warwick J, Allgood PC, Kearins O, Tappenden N, O\u2019Sullivan E, Lawrence G. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol. 2008;168:98\u2013104.","journal-title":"Am J Epidemiol"},{"key":"1841_CR14","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/jnci\/djad230","volume":"116","author":"L de Munck","year":"2023","unstructured":"de Munck L, Eijkelboom AH, Otten JDM, Broeders MJM, Siesling S. Method of primary breast cancer detection and the disease-free interval, adjusting for lead time. J Natl Cancer Inst. 2023;116:370\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"1841_CR15","unstructured":"Swiss Cancer Regsitries: Description of the legally binding data dictionary for all cancer registries under the new law on cancer registrations; 2019."},{"key":"1841_CR16","volume-title":"Guidelines for quality assurance in breast cancer screening and diagnosis","author":"N Perry","year":"2006","unstructured":"Perry N. Guidelines for quality assurance in breast cancer screening and diagnosis. Luxembourg: Office for Official Publications of the European Communities; 2006."},{"key":"1841_CR17","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/sj.bjc.6604638","volume":"99","author":"SW Duffy","year":"2008","unstructured":"Duffy SW, Lynge E, Jonsson H, Ayyaz S, Olsen AH. Complexities in the estimation of overdiagnosis in breast cancer screening. Br J Cancer. 2008;99:1176\u20138.","journal-title":"Br J Cancer"},{"key":"1841_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0033-8389(05)70191-3","volume":"38","author":"L Tab\u00e1r","year":"2000","unstructured":"Tab\u00e1r L, Vitak B, Chen HH, Duffy SW, Yen MF, Chiang CF, Krusemo UB, Tot T, Smith RA. The Swedish Two-County Trial twenty years later Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am. 2000;38:625\u201351.","journal-title":"Radiol Clin North Am"},{"key":"1841_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.4103\/0973-1482.167614","volume":"14","author":"N Marwah","year":"2018","unstructured":"Marwah N, Batra A, Marwah S, Gupta V, Shakya S, Sen R. Correlation of proliferative index with various clinicopathologic prognostic parameters in primary breast carcinoma: a study from North India. J Cancer Res Ther. 2018;14:537\u201342.","journal-title":"J Cancer Res Ther"},{"key":"1841_CR20","doi-asserted-by":"publisher","first-page":"e2330961","DOI":"10.1001\/jamanetworkopen.2023.30961","volume":"6","author":"J Lee","year":"2023","unstructured":"Lee J, Lee Y-J, Bae SJ, Baek SH, Kook Y, Cha YJ, Lee JW, Son BH, Ahn SH, Lee HJ, Gong G, Jeong J, Lee SB, Ahn SG. Ki-67, 21-gene recurrence score, endocrine resistance, and survival in patients with breast cancer. JAMA Netw Open. 2023;6:e2330961.","journal-title":"JAMA Netw Open"},{"key":"1841_CR21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12885-021-07917-2","volume":"21","author":"C Herrmann","year":"2021","unstructured":"Herrmann C, Morant R, Walser E, Mousavi M, Th\u00fcrlimann B. Screening is associated with lower mastectomy rates in eastern Switzerland beyond stage effects. BMC Cancer. 2021;21:229.","journal-title":"BMC Cancer"},{"key":"1841_CR22","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.amjsurg.2019.04.006","volume":"219","author":"M Jay","year":"2020","unstructured":"Jay M, Creelman B, Baliski C. Patient reported outcomes associated with surgical intervention for breast cancer. Am J Surg. 2020;219:816\u201322.","journal-title":"Am J Surg"},{"key":"1841_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/oxfordjournals.aje.a112046","volume":"100","author":"S Shapiro","year":"1974","unstructured":"Shapiro S, Goldberg JD, Hutchison GB. Lead time in breast cancer detection and implications for periodicity of screening. Am J Epidemiol. 1974;100:357\u201366.","journal-title":"Am J Epidemiol"},{"key":"1841_CR24","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.breast.2013.07.046","volume":"22","author":"B Cox","year":"2013","unstructured":"Cox B, Sneyd MJ. Bias in breast cancer research in the screening era. Breast (Edinburgh, Scotland). 2013;22:1041\u20135.","journal-title":"Breast (Edinburgh, Scotland)"},{"key":"1841_CR25","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.3390\/cancers16071326","volume":"16","author":"L Schumann","year":"2024","unstructured":"Schumann L, Hadwiger M, Eisemann N, Katalinic A. Lead-time corrected effect on breast cancer survival in Germany by mode of detection. Cancers. 2024;16:1326.","journal-title":"Cancers"},{"key":"1841_CR26","doi-asserted-by":"publisher","first-page":"djv014","DOI":"10.1093\/jnci\/djv014","volume":"107","author":"PM Marcus","year":"2015","unstructured":"Marcus PM, Prorok PC, Miller AB, DeVoto EJ, Kramer BS. Conceptualizing overdiagnosis in cancer screening. J Natl Cancer Inst. 2015;107:djv014.","journal-title":"J Natl Cancer Inst"},{"key":"1841_CR27","first-page":"3","volume":"34","author":"LF Ellison","year":"2023","unstructured":"Ellison LF, Saint-Jacques N. Five-year cancer survival by stage at diagnosis in Canada. Health Rep. 2023;34:3\u201315.","journal-title":"Health Rep"},{"key":"1841_CR28","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.3390\/curroncol29080444","volume":"29","author":"AN Wilkinson","year":"2022","unstructured":"Wilkinson AN, Billette J-M, Ellison LF, Killip MA, Islam N, Seely JM. the impact of organised screening programs on breast cancer stage at diagnosis for Canadian women Aged 40\u201349 and 50\u201359. Curr oncol (Toronto, Ont). 2022;29:5627\u201343.","journal-title":"Curr oncol (Toronto, Ont.)"},{"key":"1841_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12916-019-1252-6","volume":"17","author":"W He","year":"2019","unstructured":"He W, Eriksson L, T\u00f6rnberg S, Strand F, Hall P, Czene K. Discontinuation of adjuvant hormone therapy among breast cancer patients not previously attending mammography screening. BMC Med. 2019;17:24.","journal-title":"BMC Med"},{"key":"1841_CR30","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10549-011-1363-z","volume":"128","author":"MJ Aarts","year":"2011","unstructured":"Aarts MJ, Voogd AC, Duijm LEM, Coebergh JWW, Louwman WJ. Socioeconomic inequalities in attending the mass screening for breast cancer in the south of the Netherlands\u2013associations with stage at diagnosis and survival. Breast Cancer Res Treat. 2011;128:517\u201325.","journal-title":"Breast Cancer Res Treat"},{"key":"1841_CR31","doi-asserted-by":"publisher","first-page":"e0275525","DOI":"10.1371\/journal.pone.0275525","volume":"17","author":"RM Pokora","year":"2022","unstructured":"Pokora RM, B\u00fcttner M, Schulz A, Schuster AK, Merzenich H, Teifke A, Michal M, Lackner K, M\u00fcnzel T, Zeissig SR, Wild PS, Singer S, Wollschl\u00e4ger D. Determinants of mammography screening participation-a cross-sectional analysis of the German population-based Gutenberg Health Study (GHS). PLoS ONE. 2022;17:e0275525.","journal-title":"PLoS ONE"},{"key":"1841_CR32","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/ijc.30856","volume":"141","author":"A Feller","year":"2017","unstructured":"Feller A, Schmidlin K, Bordoni A, Bouchardy C, Bulliard J-L, Camey B, Konzelmann I, Maspoli M, Wanner M, Clough-Gorr KM. Socioeconomic and demographic disparities in breast cancer stage at presentation and survival: a Swiss population-based study. Int J Cancer. 2017;141:1529\u201339.","journal-title":"Int J Cancer"},{"key":"1841_CR33","doi-asserted-by":"publisher","first-page":"812776","DOI":"10.3389\/fpubh.2022.812776","volume":"10","author":"V Jolidon","year":"2022","unstructured":"Jolidon V, de Prez V, Bracke P, Bell A, Burton-Jeangros C, Cullati S. Revisiting the effects of organized mammography programs on inequalities in breast screening uptake: a multilevel analysis of nationwide data from 1997 to 2017. Front Public Health. 2022;10:812776.","journal-title":"Front Public Health"},{"key":"1841_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ypmed.2017.07.025","volume":"103","author":"JL Sandoval","year":"2017","unstructured":"Sandoval JL, Theler J-M, Cullati S, Bouchardy C, Manor O, Gaspoz J-M, Guessous I. Introduction of an organised programme and social inequalities in mammography screening: a 22-year population-based study in Geneva, Switzerland. Prev Med. 2017;103:49\u201355.","journal-title":"Prev Med"},{"key":"1841_CR35","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1002\/cncr.32859","volume":"126","author":"SW Duffy","year":"2020","unstructured":"Duffy SW, Tab\u00e1r L, Yen AM-F, Dean PB, Smith RA, Jonsson H, T\u00f6rnberg S, Chen SL-S, Chiu SY-H, Fann JC-Y, Ku MM-S, Wu WY-Y, Hsu C-Y, Chen Y-C, Svane G, Azavedo E, Grundstr\u00f6m H, Sund\u00e9n P, Leifland K, Frodis E, Ramos J, Epstein B, \u00c5kerlund A, Sundbom A, Bord\u00e1s P, Wallin H, Starck L, Bj\u00f6rkgren A, Carlson S, Fredriksson I, et al. Mammography screening reduces rates of advanced and fatal breast cancers: results in 549,091 women. Cancer. 2020;126:2971\u20139.","journal-title":"Cancer"},{"key":"1841_CR36","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1200\/JCO.2023.41.16_suppl.552","volume":"41","author":"RA Smith","year":"2023","unstructured":"Smith RA, Duffy SW, Yen AM-F, Tab\u00e1r L, Lin AT-Y, Chen SL-S, Hsu C-Y, Dean P, Chen TH-H. Beneficial effect of repeated participation in breast cancer screening upon survival. JCO. 2023;41:552.","journal-title":"JCO"},{"key":"1841_CR37","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/ijc.32767","volume":"147","author":"A Katalinic","year":"2020","unstructured":"Katalinic A, Eisemann N, Kraywinkel K, Noftz MR, H\u00fcbner J. Breast cancer incidence and mortality before and after implementation of the German mammography screening program. Int J Cancer. 2020;147:709\u201318.","journal-title":"Int J Cancer"},{"key":"1841_CR38","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1001\/jama.2017.19130","volume":"319","author":"SK Plevritis","year":"2018","unstructured":"Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, Song J, de Koning HJ, Trentham-Dietz A, van Ravesteyn NT, Gangnon R, Chandler Y, Li Y, Xu C, Ergun MA, Huang H, Berry DA, Mandelblatt JS. Association of screening and treatment with breast cancer mortality by molecular subtype in US women, 2000\u20132012. JAMA. 2018;319:154\u201364.","journal-title":"JAMA"},{"key":"1841_CR39","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/0962280219832901","volume":"29","author":"L Abrahamsson","year":"2020","unstructured":"Abrahamsson L, Isheden G, Czene K, Humphreys K. Continuous tumour growth models, lead time estimation and length bias in breast cancer screening studies. Stat Methods Med Res. 2020;29:374\u201395.","journal-title":"Stat Methods Med Res"},{"key":"1841_CR40","doi-asserted-by":"crossref","unstructured":"The benefits and harms of breast cancer screening: an independent review. Lancet (London, England) 2012, 380:1778\u20131786","DOI":"10.1016\/S0140-6736(12)61611-0"},{"key":"1841_CR41","doi-asserted-by":"publisher","first-page":"471","DOI":"10.7326\/M21-3577","volume":"175","author":"MD Ryser","year":"2022","unstructured":"Ryser MD, Lange J, Inoue LYT, O\u2019Meara ES, Gard C, Miglioretti DL, Bulliard J-L, Brouwer AF, Hwang ES, Etzioni RB. Estimation of breast cancer overdiagnosis in a U.S. breast screening cohort. Ann Intern Med. 2022;175:471\u20138.","journal-title":"Ann Intern Med"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-024-01841-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-024-01841-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-024-01841-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T21:56:53Z","timestamp":1732053413000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-024-01841-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1841"],"URL":"https:\/\/doi.org\/10.1186\/s13058-024-01841-6","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,27]]},"assertion":[{"value":"22 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective cohort study was submitted to the Ethics Commission of Eastern Switzerland (EKOS-23\/061). It was ruled to be a quality control covered by the informed patient consent of the MSP. All data was pseudonymized by the Cancer Registry of Eastern Switzerland prior to analyses.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RM, MB, and AE work for the Cancer League of Eastern Switzerland, which is responsible for the mammography screening program \u201cdonna\u201d and the Cancer Registry of Eastern Switzerland. All other authors do not declare any conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}